EUVIMEDEUVIMED entdecken
VergleichsstudieEvaluationsstudieOpen Access · CC BY 4.0

Comparative evaluation of Savanna HSV 1+2/VZV multiplex assay and Simplexa HSV 1&2 and VZV direct kits for rapid molecular detection of HSV-1, HSV-2, and VZV

Blake W Buchan iD, Paul A Granato iD, Jessica S Hoff, Marie Wisniewski, Adam Nielsen, Lavannya Sabharwal, Derek Gerstbrein, Amorina Purpora, Puspa Bhattarai, Julie O'Neill, Kevin Knect, Cecelia Plummer und 1 weitere

Microbiology Spectrum · 2026

DOI: 10.1128/spectrum.03654-25 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Blake W Buchan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Herpesvirus 2, Human, Herpesvirus 1, Human, Herpesvirus 3, Human, Molecular Diagnostic Techniques. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: QuidelOrtho.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herpes simplex virus (HSV-1 and HSV-2) and varicella-zoster virus (VZV) cause cutaneous and mucocutaneous lesions. Primary infection and secondary reactivations affect the mouth, genitalia, and dermis at other bodily regions. Accurate clinical diagnosis without laboratory confirmation can be difficult since lesions caused by these viruses are nondescript, and areas of bodily infection can overlap. Rapid molecular test results have been shown to reduce the time to definitive diagnosis, providing additional opportunities for patient counseling, antiviral therapy, and appropriate infection prevention measures. A molecular, multiplexed HSV + VZV assay allows both viruses to be tested simultaneously from a single lesion swab. This could potentially enhance diagnostic accuracy through laboratory confirmation, thus minimizing dependence on clinical judgment alone. The recently Food and Drug Administration (FDA)-approved Savanna HSV 1+2/VZV multiplex assay has not been widely evaluated against other FDA-approved assays. This is the first report evaluating the clinical performance of the Savanna HSV 1+2/VZV assay compared to independent assays for HSV and VZV. Results indicated that the Savanna HSV 1+2/VZV assay was comparable to the Diasorin Simplexa HSV 1&2 Direct and VZV Direct assays. IMPORTANCE Lesion-causing viruses, herpes simplex (HSV-1 and HSV-2) and varicella-zoster virus (VZV), are common and difficult to distinguish clinically. Each can be found over any area of the body but have different treatment regimens and considerations for infectivity and future outbreak management. Laboratory analysis by molecular assay is the gold standard for these viruses, but it can take hours to days and is reliant on the clinician choosing the correct virus to test the first time, or risk being outside the treatment window. A rapid molecular assay that detects all three viruses simultaneously was developed and recently approved by the Food and Drug Administration (FDA). Here, we provide data highlighting the clinical performance of the Savanna HSV 1+2/VZV assay and its ability to detect across anatomical locations and ages. These data indicate that the Savanna assay is comparable to individual assays for each viral target, providing the opportunity for enhanced diagnostic accuracy of lesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpesvirus 2, HumanHerpesvirus 1, HumanHerpesvirus 3, HumanMolecular Diagnostic TechniquesHerpes SimplexHumansReagent Kits, DiagnosticSensitivity and Specificity

Stichwörter der Autor:innen

herpes simplex virusmultiplex assayvaricella-zoster virus

Substanzen

Reagent Kits, Diagnostic

Autor:innen und Institutionen

  • Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Laboratory Alliance of Central New York, Liverpool, New York, USA.
  • The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

ORCID-Profile: Blake W Buchan, Paul A Granato, Preeti Pancholi

Förderung

  • QuidelOrtho

Zitieren

APA

Buchan, B. W., Granato, P. A., Hoff, J. S., Wisniewski, M., Nielsen, A., Sabharwal, L., Gerstbrein, D., Purpora, A., Bhattarai, P., O'Neill, J., Knect, K., Plummer, C., & Pancholi, P. (2026). Comparative evaluation of Savanna HSV 1+2/VZV multiplex assay and Simplexa HSV 1&2 and VZV direct kits for rapid molecular detection of HSV-1, HSV-2, and VZV. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03654-25

Vancouver

Buchan BW, Granato PA, Hoff JS, Wisniewski M, Nielsen A, Sabharwal L, et al. Comparative evaluation of Savanna HSV 1+2/VZV multiplex assay and Simplexa HSV 1&2 and VZV direct kits for rapid molecular detection of HSV-1, HSV-2, and VZV. Microbiology Spectrum. 2026. doi:10.1128/spectrum.03654-25

BibTeX
@article{Buchan2026,
  author = {Buchan, Blake W and Granato, Paul A and Hoff, Jessica S and Wisniewski, Marie and Nielsen, Adam and Sabharwal, Lavannya and Gerstbrein, Derek and Purpora, Amorina and Bhattarai, Puspa and O'Neill, Julie and Knect, Kevin and Plummer, Cecelia and Pancholi, Preeti},
  title = {Comparative evaluation of Savanna HSV 1+2/VZV multiplex assay and Simplexa HSV 1&2 and VZV direct kits for rapid molecular detection of HSV-1, HSV-2, and VZV},
  journal = {Microbiology Spectrum},
  year = {2026},
  doi = {10.1128/spectrum.03654-25}
}
Kostenlos starten →